The company’s commercial momentum remains anchored in the expansion of blue-light cystoscopy technology. During the quarter, Photocure installed six new Saphira towers in the U.S., bringing its total active account base to 436—a 20% increase compared to the second quarter of 2025. European operations saw similar traction, with 87 Olympus Visera Elite III systems deployed since early 2025 alongside various rigid system upgrades.

CEO Dan Schneider highlighted the acquisition of Vesica Health as a pivotal step toward integrating non-invasive biomarker testing with existing imaging franchises. The addition of the AssureMDx test aims to improve early detection and risk stratification for bladder cancer, with initial revenue expected by 2027. Furthermore, the company is preparing for a significant regulatory development in the U.S., where the FDA plans to initiate the reclassification of blue-light cystoscopy equipment later this year. This move is expected to simplify the market landscape and encourage broader manufacturer participation. Reflecting this optimism, Photocure has raised its full-year product revenue growth forecast to a range of 8% to 11%.